A recent study shows the capacity of anti-VEGFs to enter human breast milk.

Rethinking our approach to the use of energy and resources could help transform our relationship with the environment.

Higher productivity, lower hold times, lower costs… continuous processing for monoclonal antibodies could offer a number of advantages.

We only have one planet. We must play a responsible role when it comes to its care.

Can’t offer an “affordable” price? Then say goodbye to market exclusivity.

Industry experts share how their therapeutic products are shaping the future of the pharmaceutical landscape.

Is the regulator environment changing fast enough to accommodate the vast array of microbiome-based therapeutics beginning to emerge?

Looking for an experienced partner to simplify the development and manufacture of a new antibody-drug conjugate (ADC)?

Some have dismissed excitement about the microbiome as “hype,” but real results are beginning to be seen.

Nominations for The Medicine Maker 2019 will close on Friday, October 25.